Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
Syntara (ASX:SNT) has 0.24% of its shares on issue reported as short positions as of 7 July 2026, or about 4,806,305 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.11 percentage points. SNT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Syntara (SNT) Short Interest
Syntara (ASX:SNT) had 0.24% of shares reported as short positions as of 7 July 2026, representing 4,806,305 shares. Syntara operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads SNT today
- Zanger BreakoutWatchScore 7rank 1876 of 1947
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutWatchScore 10rank 973 of 1533
- Quality compoundersNot a candidate
Prices to 9 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
SNT fundamentals
In the year to 30 Jun 2026, Syntara (ASX:SNT) recorded revenue of A$6.8M and a net loss after tax of A$9.0M. A year earlier it recorded revenue of A$7.5M and a net loss after tax of A$7.9M. Year-on-year growth: revenue −8.6% (FY). Net margin −131.6% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 29 Sep 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest SNT news
All news- Syntara (ASX:SNT): Myelofibrosis Trial Plans Put Clinical Pipeline in Focus - Kalkine
googlenews · 9 Oct 2026
- Further significant results from SNT-4728 iRBD Phase 2 trial
asx · 6 Oct 2026
- Syntara Limited Grants 1,581,746 Performance Rights to Employees, Including Key Executive Wolfgang Jarolimek
kalkine · 5 Oct 2026
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss SNT
Start a research thread or post the first pulse update